AVTEAerovate Therapeutics, Inc.

Nasdaq aerovatetx.com


$ 17.98 $ -1.79 (-9.04 %)    

Wednesday, 22-May-2024 15:59:11 EDT
QQQ $ 454.82 $ -0.09 (-0.02 %)
DIA $ 398.57 $ -2.12 (-0.53 %)
SPY $ 530.36 $ -1.53 (-0.29 %)
TLT $ 91.26 $ 0.11 (0.12 %)
GLD $ 225.37 $ -4.12 (-1.84 %)
$ 18
$ 19.38
$ 0.00 x 0
$ 0.00 x 0
$ 17.05 - $ 19.38
$ 9.41 - $ 32.42
359,844
na
500.32M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-25-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

 aerovate-therapeutics-presents-baseline-data-from-phase-2b-portion-of-impahct-trial-at-ats-2024-international-conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study ...

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

 aerovate-therapeutics-q1-2024-gaap-eps-083-misses-074-estimate

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate ...

 ermenegildo-zegna-reports-fy23-results-joins-altice-usa-herbalife-and-other-big-stocks-moving-lower-on-friday

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday. Shares of Ermenegildo Zegna N.V. (NYSE:...

 wells-fargo-maintains-overweight-on-aerovate-therapeutics-maintains-35-price-target

Wells Fargo analyst Tiago Fauth maintains Aerovate Therapeutics (NASDAQ:AVTE) with a Overweight and maintains $35 price target.

 aerovate-therapeutics-to-present-patient-baseline-characteristics-of-the-phase-2b-portion-of-the-phase-2bphase-3-impahct-trial-at-the-american-thoracic-society-2024-international-conference

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve ...

 aerovate-therapeutics-q4-2023-gaap-eps-074-misses-070-estimate

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate ...

 jefferies-assumes-aerovate-therapeutics-at-buy-raises-price-target-to-65

Jefferies analyst Eun Yang assumes Aerovate Therapeutics (NASDAQ:AVTE) with a Buy rating and raises Price Target to $65.

 aerovate-therapeutics-board-of-directors-appoints-habib-dable-as-board-chair

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve ...

 aerovate-therapeutics-q3-eps-071-misses-069-estimate-cash-cash-equivalents-and-available-for-sale-securities-of-1352m-will-be-sufficient-to-fund-operations-into-2026

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate ...

 stocks-that-hit-52-week-lows-on-thursday

  During the session on Thursday, 461 stocks hit new 52-week lows.

 stocks-that-hit-52-week-lows-on-friday

  Friday's session saw 169 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-monday

  Monday's session saw 175 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-friday

  Friday's session saw 225 companies set new 52-week lows.

 aerovate-therapeutics-q2-eps-076-misses-070-estimate

Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION